Co-op: Analytical Development
Company Overview:
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology & oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. For more information, please visit www.primemedicine.com.
Co-op: Analytical Development
(Fall 2026 Cycle)
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replace the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.
We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefits to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with a diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.
Co-op Assignment Overview
Prime Medicine is seeking a diligent, motivated, and enthusiastic co-op for the Fall 2026 cycle who has interest in state-of-the-art analytical technologies including HPLC, LC-MS, and capillary electrophoresis to join the analytical development (AD) team. The successful candidate will be able to participate in the development of separation-based analytical methods for the Prime Editor delivery platform and work cross-functionally to advance the Prime pipeline. Also, this co-op student will have hands-on opportunities to gain exposure to a broader range of analytical techniques (such as flow cytometry), gaining familiarity with scientific and regulatory requirements for phase-appropriate analytical testing. There will also be valuable opportunities to participate in other cross-functional projects that are crucial to the success of in vivo and ex vivo gene editing therapeutic drug development.
Primary Responsibilities:
- Participate in separation-based method (HPLC, LC-MS) development to assess lipid nanoparticle (LNP) drug products and their components. Assist senior-level scientists with buffer preparation, maintenance of instruments, and developing up-to-date analytical methods that help to increase in-process analytics capacity.
- Participate in cell-based method (flow cytometry) development to assess cell therapy drug products. Support the maintenance of instruments.
- Support the phase-appropriate product development (PD) sample analyses, release testing, and stability studies for the characterization and release of cell and gene therapy drug products, drug substances, and critical raw materials.
- Document, present, and communicate experimental data and conclusions in an electronic notebook, following cGMP documentation practices.
- Data analysis, interpretation, and presentation within the team.
Qualifications:
- Currently enrolled in a B.S. or M.S. program in biochemistry, chemistry, chemical engineering, pharmaceutical science, or a related field.
- Basic knowledge of separation sciences and technologies.
- Ability to handle multiple projects in a fast-paced environment.
- Excellent troubleshooting and communication skills.
- Ability to work independently and within a team.
- Skilled in documenting findings and activities in comprehensive reports and ensuring proper inventory of materials and analytical equipment.
Preferred Qualifications:
- Hands-on experience with LC-MS, capillary electrophoresis, and/or cell culture is preferred.
- Previous co-op experience in the biotechnology industry.
- Independently motivated, detail-oriented, and excellent problem-solving abilities.
What We Offer:
- A cutting-edge scientific team dedicated to mentorship and networking
- Experience in the field of gene editing and analytical development/early-stage QC
- Participation in regular scientific seminars with industry experts
The pay range reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on several factors including, but not limited to, relevant experience, skills, and education.
U.S. Pay Range
$23—$33 USD
Prime Medicine is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, age, sexual orientation, gender identity, disability, veteran status, or any other classification protected by law.